(RTTNews) - Eurofins Technologies (ERFSF.PK) said that it has launched its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).
The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant.
The company noted that GSD NovaType III SARS-CoV-2 will be available as a research-use-only kit by the 9th of June. A CE marked version is expected by the second half of June.
Eurofins Technologies is committed to continue to rapidly adapt its product offering to the meet the evolving challenges of SARS-CoV-2.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
